A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pediatric (\< 18 years) and adult (≥ 18 years) participants with biopsy-proven and measurable Kaposi Sarcoma (KS) as defined in the KS Manual of Procedures (MOP).
* No urgent clinical indication for immediate cytotoxic chemotherapy. Participants who have received cytotoxic chemotherapy \> 4 weeks prior to screening are eligible.
* KS stage:
* \< 18 years:
* 1A (Mild): disease limited to skin, flat oral mucosal lesions, and/or flesh colored subcutaneous nodules, total \<10 lesions.
* 1B (Moderate): having any of the following features, alone or in combination: a total of 10-19 hyperpigmented skin/oral lesions, nodular oral involvement, conjunctival eye involvement, or exophytic mass.
* ≥ 18 years:
* T0: confined to skin and/or lymph nodes and/or minimal oral lesions.
* T1: limited to tumor-associated edema of cutaneous lesions without functional impairment or flat oral lesions.
* Performance Status:
* \< 18 years:
* Lansky performance status \> 70%
* ≥ 18 years:
* Easter Cooperative Oncology Group (ECOG) performance status ≤ 2
* Participants must have adequate organ function, as defined by the following:
* Bilirubin (direct or total) within normal range, or total bilirubin \<3.0 mg/dl for participants with Gilbert syndrome.
* Calculated creatinine clearance ≥ 30 mL/min for participants ≥ 12 years (see Appendix III); creatinine \<1.5 Upper Limit Normal (ULN) for participants \< 12 years.
* Hemoglobin \> 9 g/dL;…